Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments

A tumor and cancer technology, applied in the field of cancer symptoms or cancer treatment symptoms, treatment or prevention of cancer, can solve the problem that the response of tumor chemotherapy is not very good

Inactive Publication Date: 2010-03-31
FONTERRA COOP GRP LTD
View PDF32 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] It was previously reported that tumors did not respond well to chemotherapy in all cases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
  • Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
  • Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0341] Bovine lactoferrin with greater than 90% purity is from Fonterra Co-operative Group. To prepare apo-Lf (apo-Lf), a solution of approximately 80 mg / mL Lf in milliQ water (pH~5.7) was adjusted to pH 2.08 by careful addition of 6M HCl. The solution was stirred at room temperature for 1 hour and then dialyzed against 10 volumes of 0.1 M citric acid overnight at 4°C using SpectraPor tubes with a nominal 3.5 kDa molecular weight cut-off (Spectrum Companies, Ranco Dominguez, CA, USA). The dialysate was changed twice within 24 h, and then the Lf solution was freeze-dried to a white semi-crystalline powder. To prepare 50% iron-saturated lactoferrin, a solution of 8% lactoferrin in 0.1M sodium bicarbonate was adjusted to pH 8.2 by careful addition of 6M NaOH. Addition of a suitable volume of 50 mM iron nitrilotriacetate (Fe-NTA) (Bates et al., 1967; Brock & Arzabe, 1976) yielded ~50% saturated lactoferrin (considering the purity of Lf and its natural ~12% iron saturation). Aft...

Embodiment 2

[0342] This example shows that milk fat inhibits the growth of EL-4 tumors, whereas milk fat enriched in conjugated linoleic acid and vacantoleic acid is ineffective.

[0343] Groups containing 6 C57BL / 6 mice were fed either basic AIN-93 chow, or the same chow replaced with 120 g of milk fat or fortified milk fat per 2.4 Kg of chow, representing -71% fat content of the chow. 2 x 10 5 EL-4 tumor cells were tested subcutaneously in mice. Tumor size (measured by perpendicular two diameters in centimeters) was monitored until day 91, or until tumors reached 1 cm in diameter. Each point represents the mean tumor size with 95% confidence interval for 6 mice or the indicated number of mice.

[0344] Compared with the control diet, fortified milk fat slowed tumor growth by 25% on day 49, but the effect was not significant ( figure 1 ). In sharp contrast, in 2 out of 6 mice milk fat completely tissue tumor development. Tumor growth in the other four mice fed the milk fat diet was ...

Embodiment 3

[0345] This example shows that milk fat works synergistically with immunotherapy to eradicate EL-4 tumors.

[0346] Tumors were established in groups of 5 mice fed fortified milk fat, milk fat or a control diet, as described in Example 2 above. Tumor size (measured by perpendicular two diameters in centimeters) was monitored. When tumors reached ~0.4 cm in diameter, DNA-liposome complexes containing 60 μg of B7-1 expression plasmid were injected into the tumors. The times of plasmid administration are indicated by arrows. Tumor size (measured by perpendicular two diameters in centimeters) was monitored until day 91, or until tumors reached 1 cm in diameter. Tumors of this particular size remained partially sensitive to B7-1 immune gene therapy, as evidenced by the fact that control tumors in four mice regressed slowly for a week and then grew again. However, during the 4 weeks after injection of the B7-1 plasmid, the tumor in 1 mouse regressed and disappeared ( figure 2 )...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The present invention relates to administration of milk fat or a milk fat analogue, optionally with at least one additional therapeutic factor, preferably lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof, to inhibit tumour formation or growth, maintain or improve one or more of the white blood cell count, the red blood cell count, or the myeloid cell count, reduce cachexia, mucositis, and anemia, stimulate the immune system and treat or prevent cancer and the symptoms of cancer and side-effects of cancer therapies. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided.

Description

field of invention [0001] The present invention relates to enhancing immunity or blood, inhibiting tumor formation by administering milk fat or milk fat analogues, optionally with at least one other therapeutic agent, such as an antineoplastic agent preferably selected from lactoferrin (including iron-lactoferrin) or growth and methods of treating or preventing cancer, cancer symptoms, or cancer treatment symptoms. The methods and medical uses of the present invention can be carried out by using diet (as food or food supplement), nutraceutical or pharmaceutical composition. Compositions for use in the methods of the invention are also provided. Background of the invention [0002] Milk is a rich biological fluid that provides nutrition during periods of rapid growth and development for infants. Therefore, in addition to the substances necessary for the development of the baby, it also contains many growth regulators. [0003] The health benefits of milk intake with respec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/40A23C13/12A23C15/00A23C17/00A23C21/00A61K31/592A61K31/593A61K36/48A61P25/00A61P37/00
CPCA23V2002/00A61K38/40A61K35/20A23C17/00A23C2240/05A61K31/593A61K36/48A23C15/12A61K31/592A23C13/12A61P1/04A61P7/00A61P7/06A61P11/00A61P15/00A61P17/00A61P25/00A61P31/00A61P35/00A61P35/02A61P35/04A61P37/00A61P37/04A61K2300/00A23V2250/194A23V2200/308
Inventor 加格特·拉科施·康旺杰夫里·威恩·克里塞森孙学英凯·帕特丽夏·帕尔马托阿拉斯代尔·凯尼斯·修·迈克基布恩
Owner FONTERRA COOP GRP LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products